The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001068358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
10/07/2026
Date registered
Help: Date registered
28/08/2026
Date last updated
Help: Date last updated
28/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
28/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The effects of heat on the heart and lungs in healthy young and older adults
Scientific title
The effects of whole-body passive heating on cardio-respiratory function in young and older healthy adults.
Additional trial identifiers [1] 317816 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Heat related cardiovascular strain 342742 0
Condition category
Condition code
Cardiovascular 338873 338873 0 0
Normal development and function of the cardiovascular system

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Data collection protocol:
Participants will be asked to attend 2 sessions at the University of Sydney and 1 session external to the University. The time involvement will be approximately 5 hours for the university visits and 1.5-2 hours for the external visit. The visits will occur based on participant availability. Intervention adherence and fidelity will be monitored by the research team throughout each study visit.

Initial Telephone Pre-Screen:
When a person indicates their interest in the study, they will undergo a telephone screening to discuss the study and determine initial eligibility for the study. This phone call will take approximately 30 minutes.

Preliminary session (Visit 1):
Prior to the preliminary session, potential participants will do a telephone screening which will be checked and signed off by cardiologist Dr Lai Heng Foong to confirm eligibility. During the preliminary session, we will explain all procedures with the participants. In addition, they will be introduced to all of the equipment and measuring devices that we will be using for the familiarisation (visit 1) and experimental (visit 3) sessions. We will give each participant the opportunity to read the Information Sheet and Consent Form documents (which they will have been provided with prior to attending the laboratory). Besides, we will have participants perform routine pulmonary function testing (PFT) on the preliminary visit to obtain baseline characteristics from participants. During this visit, participants will be thoroughly familiarised with the procedure of assessing the psychophysical properties of respiratory muscle force production. These data are integral to the study design insofar as they help establish test-retest reproducibility for the method – information that is presently unknown. This reproducibility examination will require participants to complete 5 repeat blocks of the psychophysical assessment of respiratory muscle force, separated by at least 3-5 minutes. During this time, heart rate and blood pressure will be monitored and recorded.

Screening Session (Visit 2):
This screening session will take approximately 1-1.5 hours. Participants will be asked to undergo an echocardiograph which involves the participant laying supine while images of the heart are scanned using an ultrasound. These sessions will be carried out at one of the clinics within Sydney Cardiology Group (City, Bella Vista, Chatswood), under the supervision of the study cardiologist, Fiona Foo. If the cardiologist deems no abnormal findings on the echocardiogram, then the participant will be eligible to participate in visit 3.

Experimental trial (Visit 3):
Upon arrival to the laboratory, participants will be asked to provide a urine sample and weigh themselves nude (in private) and self-insert the rectal thermistor. ECG will be applied to the skin to measure heart rate and a cuff placed on the arm for measures of blood pressure. Temperature sensors will be placed on the skin at four sites across the body for measurement of skin temperature. Finally, participants will don a tubed lined suit covering the whole body except for the head, hands and feet, through which water will flow at different temperatures to control the participant’s core temperature. Participants will be asked to lay quietly for a period of 15 minutes while baseline measurements are recorded and 34°C water is circulated throughout the suit. Following this, 50°C water will be circulated through the suit until rectal temperature increases by 0.5°C, 1.0°C and 1.5°C.

At each time point (baseline, +0.5°C, +1.0°C, +1.5°C), a cardiac assessment using an ultrasound will be performed by a trained professional, and participants will complete a short series of breathing tasks to assess their sensation of respiratory muscle effort. Following the last measurement point, cold water (20°C) will circulate throughout the suit until rectal temperature returns to baseline values. An additional cardiac assessment will be conducted when core temperature returns to baseline values. Following this, the participants will be de-instrumented, and a nude weight will be recorded. Once the experimental trial is completed, participants will be weighed once again and then de-instrumented and given the opportunity to shower in the adjacent facility.

Prior to the experimental visit, participants will be asked to abstain from alcohol and caffeine, avoid strenuous exercise in the 12 h before each experimental session, and consume a light meal along with 500 ml of water ~2 h before arriving at the laboratory.

Both young and older healthy participants will be assessed and these cohorts will be compared.

Intervention fidelity will be ensured through a standardised study protocol applied to all participants. Water temperature, core temperature and duration of each intervention stage will be monitored by the research team. Predefined core temperature targets (+0.5°C, +1.0°C and +1.5°C) will be used to standardise the heating exposure. Any protocol deviations or premature termination of the intervention will be documented.
Intervention code [1] 334663 0
Treatment: Other
Description of the comparator or control
There is no separate control group. This is a repeated-measures physiological study in which each participant serves as their own control. Participants complete a 15-minute baseline resting period with 34°C water circulating through the suit, during which baseline cardiovascular and respiratory measurements are obtained. Measurements collected during this thermoneutral baseline condition serve as the reference comparator for measurements obtained during passive heating (50°C water circulation) at core temperature increases of +0.5°C, +1.0°C and +1.5°C, with an additional set of measurements collected at recovery (20°C water circulation) when the participant's core temperature has reached baseline values. Comparisons are also made between healthy young(18-40years) and older(60-80years) adult cohorts.
Control group
Active

Outcomes
Primary outcome [1] 346090 0
Composite cardiac function
Timepoint [1] 346090 0
At each time point of core temperature (baseline, +0.5°C, +1.0°C, +1.5°C) and following heating when rectal temperature returns to baseline values, when an additional cardiac assessment will be conducted.
Secondary outcome [1] 464563 0
Heart rate
Timepoint [1] 464563 0
Heart rate will be continuously monitored throughout heating and until rectal temperature returns to baseline values.
Secondary outcome [2] 464790 0
Blood pressure
Timepoint [2] 464790 0
Blood pressure will be recorded every ten minutes throughout heating and until rectal temperature returns to baseline values.
Secondary outcome [3] 464791 0
Respiratory muscle force
Timepoint [3] 464791 0
At each time point of core temperature (baseline, +0.5°C, +1.0°C, +1.5°C) and following heating when rectal temperature returns to baseline values, when an additional cardiac assessment will be conducted.

Eligibility
Key inclusion criteria
- Aged between 18-40 years old OR 60- 80 years old.
- Non-smoker or ex-smoker (quit a minimum of 2 years prior)
- Otherwise healthy
- No difficulty understanding or speaking English
- Can lay supine for >120 minutes
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
- Negative finding on the echocardiogram
- Body mass index less than 35 kg/m2.
- Uncontrolled hypertension (either SBP > 180mmHg, or DBP > 110 mmHg at rest. ).
- Uncontrolled diabetes or severe complications of diabetes.
- Evidence of renal disease, liver disease, cerebrovascular disease, pulmonary disease, endocrine abnormalities, cognitive impairment, psychiatric disorder, substance abuse, degenerative neurological condition or any other medical condition deemed to pose risk during the study visits.
- Medication known to cause hyper- or hypo-hidrosis (except those taken for hypertension).
- Currently taking a beta-blocker.
- Evidence of current fluid and electrolyte disorders
- Current diagnosis of anemia
- Any other medical condition deemed to pose risk during the proposed testing or experiments or preclude them from completing the screening stress test.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Participants will attend one laboratory session and we will compare the responses between young and older adults who will receive the same intervention
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
From preliminary data collected from Dr Chaseling investigating myocardial flow reserve using Positron Emission Tomography, 23 participants per group provides 80% power for the myocardial flow reserve with a of 0.05 and an effect size of 0.75. No equivalent data is available for the respiratory aims of this project and, as such, this project is powered toward the cardiovascular aims of the project. As data is collected, statistical power will be reviewed, and our sample size requirements will be updated accordingly.

All statistical analyses will be performed with GraphPad Prism (version 7.0, GraphPad Software, La Jolla, CA).

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322359 0
Government body
Name [1] 322359 0
National Health and Medical Research Council (NHMRC)
Country [1] 322359 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 325279 0
None
Name [1] 325279 0
Address [1] 325279 0
Country [1] 325279 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320862 0
The University of Sydney HREC 2
Ethics committee address [1] 320862 0
Ethics committee country [1] 320862 0
Australia
Date submitted for ethics approval [1] 320862 0
30/11/2023
Approval date [1] 320862 0
24/02/2024
Ethics approval number [1] 320862 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151870 0
Dr Georgia Chaseling
Address 151870 0
The University of Sydney, Camperdown NSW 2050
Country 151870 0
Australia
Phone 151870 0
+61 421091175
Fax 151870 0
Email 151870 0
Contact person for public queries
Name 151871 0
Georgia Chaseling
Address 151871 0
The University of Sydney, Camperdown NSW 2050
Country 151871 0
Australia
Phone 151871 0
+61 421091175
Fax 151871 0
Email 151871 0
Contact person for scientific queries
Name 151872 0
Georgia Chaseling
Address 151872 0
The University of Sydney, Camperdown NSW 2050
Country 151872 0
Australia
Phone 151872 0
+61 421091175
Fax 151872 0
Email 151872 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    2023-925_Chaseling_Application approval.pdf
Informed consent form    V5-AcuteHEAT_ECHO_TEL Consent Form.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.